London, UK; Brentwood, TN, US; 22 May 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today provided an update on its VoraxazeTM marketing applications in the US and EU. VoraxazeTM is an adjunctive therapy for patients with impaired renal function who are experiencing, or at risk of, toxicity from methotrexate (“MTX”), a widely used anti-cancer agent.
